214 related articles for article (PubMed ID: 29701813)
1. A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.
Joyce JC; Carroll TD; Collins ML; Chen MH; Fritts L; Dutra JC; Rourke TL; Goodson JL; McChesney MB; Prausnitz MR; Rota PA
J Infect Dis; 2018 Jun; 218(1):124-132. PubMed ID: 29701813
[TBL] [Abstract][Full Text] [Related]
2. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.
Prausnitz MR; Goodson JL; Rota PA; Orenstein WA
Curr Opin Virol; 2020 Apr; 41():68-76. PubMed ID: 32622318
[TBL] [Abstract][Full Text] [Related]
3. A microneedle patch containing measles vaccine is immunogenic in non-human primates.
Edens C; Collins ML; Goodson JL; Rota PA; Prausnitz MR
Vaccine; 2015 Sep; 33(37):4712-8. PubMed ID: 25770786
[TBL] [Abstract][Full Text] [Related]
4. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Adigweme I; Yisa M; Ooko M; Akpalu E; Bruce A; Donkor S; Jarju LB; Danso B; Mendy A; Jeffries D; Segonds-Pichon A; Njie A; Crooke S; El-Badry E; Johnstone H; Royals M; Goodson JL; Prausnitz MR; McAllister DV; Rota PA; Henry S; Clarke E
Lancet; 2024 May; 403(10439):1879-1892. PubMed ID: 38697170
[TBL] [Abstract][Full Text] [Related]
5. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
Adigweme I; Akpalu E; Yisa M; Donkor S; Jarju LB; Danso B; Mendy A; Jeffries D; Njie A; Bruce A; Royals M; Goodson JL; Prausnitz MR; McAllister D; Rota PA; Henry S; Clarke E
Trials; 2022 Sep; 23(1):775. PubMed ID: 36104719
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children.
Sepúlveda-Amor J; Valdespino-Gómez JL; García-García Mde L; Bennett J; Islas-Romero R; Echaniz-Aviles G; de Castro JF
Vaccine; 2002 Jun; 20(21-22):2790-5. PubMed ID: 12034106
[TBL] [Abstract][Full Text] [Related]
7. Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa.
Richardson LC; Moss WJ
Pan Afr Med J; 2020; 35(Suppl 1):3. PubMed ID: 32373254
[TBL] [Abstract][Full Text] [Related]
8. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
[TBL] [Abstract][Full Text] [Related]
10. Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.
Kriss JL; Grant GB; Moss WJ; Durrheim DN; Shefer A; Rota PA; Omer SB; Masresha BG; Mulders MN; Hanson M; Linkins RW; Goodson JL
Vaccine; 2019 Sep; 37(38):5745-5753. PubMed ID: 30898393
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
[TBL] [Abstract][Full Text] [Related]
12. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.
Pan CH; Greer CE; Hauer D; Legg HS; Lee EY; Bergen MJ; Lau B; Adams RJ; Polo JM; Griffin DE
J Virol; 2010 Apr; 84(8):3798-807. PubMed ID: 20130066
[TBL] [Abstract][Full Text] [Related]
13. Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.
Joyce JC; Collins ML; Rota PA; Prausnitz MR
Adv Ther (Weinh); 2021 Oct; 4(10):. PubMed ID: 34926791
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of measles-rubella vaccination for mothers in early puerperal phase.
Hisano M; Kato T; Inoue E; Sago H; Yamaguchi K
Vaccine; 2016 Feb; 34(9):1208-14. PubMed ID: 26801065
[TBL] [Abstract][Full Text] [Related]
15. Response to measles-mumps-rubella vaccine in children on dialysis.
Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
[TBL] [Abstract][Full Text] [Related]
16. The strategy for prevention of measles and rubella prevalence with measles-rubella (MR) vaccine in Japan.
Ihara T
Vaccine; 2009 May; 27(24):3234-6. PubMed ID: 19366578
[TBL] [Abstract][Full Text] [Related]
17. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S
Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551
[TBL] [Abstract][Full Text] [Related]
19. The national measles and rubella campaign--one year on.
Commun Dis Rep CDR Wkly; 1995 Nov; 5(45):237. PubMed ID: 8541943
[No Abstract] [Full Text] [Related]
20. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
